Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials
Executive Summary
FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.
You may also be interested in...
GSK's Votrient Clears ODAC Despite Outdated Trial, FDA Safety Concerns
FDA might not always demand that a new oncologic be compared to the current standard of care if its trial was conducted before that standard was established, Office of Oncology Drug Products Director Richard Pazdur said at an Oct. 5 advisory committee meeting
GSK's Votrient Clears ODAC Despite Outdated Trial, FDA Safety Concerns
FDA might not always demand that a new oncologic be compared to the current standard of care if its trial was conducted before that standard was established, Office of Oncology Drug Products Director Richard Pazdur said at an Oct. 5 advisory committee meeting
Drug-Induced Liver Injury Workshop Offers More Questions Than Answers
To fully understand an experimental drug's potential for liver toxicity, clinical trials should be better designed to reflect real-world populations, including patients with liver disease, but neither FDA nor experts from industry and academia at a recent workshop on the topic were able to provide many answers on how to do so safely